Shares of Aethlon Medical, Inc. (NASDAQ:AEMD) have earned an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy rating.
Brokerages have set a 1 year consensus price objective of $4.88 for the company and are forecasting that the company will post ($0.07) EPS for the current quarter, according to Zacks. Zacks has also assigned Aethlon Medical an industry rank of 38 out of 257 based on the ratings given to related companies.
Separately, HC Wainwright set a $3.00 price objective on shares of Aethlon Medical and gave the company a “buy” rating in a research note on Thursday, August 9th.
Aethlon Medical (NASDAQ:AEMD) last announced its quarterly earnings data on Tuesday, November 6th. The medical equipment provider reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01). On average, equities analysts anticipate that Aethlon Medical will post -0.27 EPS for the current fiscal year.
An institutional investor recently bought a new position in Aethlon Medical stock. Millennium Management LLC bought a new position in shares of Aethlon Medical, Inc. (NASDAQ:AEMD) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 200,210 shares of the medical equipment provider’s stock, valued at approximately $238,000. Millennium Management LLC owned about 1.20% of Aethlon Medical as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 7.42% of the company’s stock.
Aethlon Medical Company Profile
Aethlon Medical, Inc, a medical device company, focuses on creating devices that address unmet medical needs in health and biodefense worldwide. The company is developing Aethlon Hemopurifier, a clinical-stage therapeutic device that eliminates life-threatening viruses from the circulatory system of infected individuals.
Featured Story: Ex-Dividend
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.